Form 8-K · Current report
Regeneron Pharmaceuticals 8-K, filed Jul 30, 2026
- Filed
- CIK
- 0000872589
- Accession no.
- 0000872589-26-000023
Summary
Regeneron Pharmaceuticals reported second-quarter 2026 revenues of $4.3 billion, up 17% year over year, with global Dupixent net sales up 38% to a new high of $6.0 billion and U.S. EYLEA HD net sales up 52% to $596 million. Regeneron said it fully repaid the Sanofi Development Balance and that the FDA and EMA accepted cemdisiran regulatory submissions for generalized myasthenia gravis for review.
Key points
- Total revenues rose 17% to $4.291 billion; GAAP EPS was $12.23 and non-GAAP EPS was $14.29.
- Global Dupixent net sales recorded by Sanofi increased 38% to $6.0 billion; U.S. EYLEA HD net sales rose 52% to $596 million; global Libtayo net sales rose 30% to $489 million.
- The Sanofi Development Balance was fully repaid as of the end of Q2 2026, which the company said will increase collaboration profits starting in Q3 2026.
- FDA and EMA accepted cemdisiran regulatory submissions for generalized myasthenia gravis; a Phase 3 trial of fianlimab plus cemiplimab in melanoma did not reach statistical significance for progression-free survival versus pembrolizumab.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On July 30, 2026, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter ended June 30, 2026. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.